| Nome |
# |
|
Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system., file e27ce427-48e2-2581-e053-d805fe0acbaa
|
477
|
|
Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era, file e27ce427-fa86-2581-e053-d805fe0acbaa
|
357
|
|
High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysis, file e27ce427-40cf-2581-e053-d805fe0acbaa
|
316
|
|
Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?, file e27ce42d-83f8-2581-e053-d805fe0acbaa
|
315
|
|
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment., file e27ce426-edaf-2581-e053-d805fe0acbaa
|
291
|
|
Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1., file e27ce426-fb81-2581-e053-d805fe0acbaa
|
282
|
|
HIV-1 Very Low Level Viremia is Associated with Virological Failure in HAART-treated Patients, file e27ce427-fa88-2581-e053-d805fe0acbaa
|
262
|
|
A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs, file e27ce427-8c10-2581-e053-d805fe0acbaa
|
258
|
|
Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting, file e27ce426-c733-2581-e053-d805fe0acbaa
|
252
|
|
The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment, file e27ce42e-dc35-2581-e053-d805fe0acbaa
|
250
|
|
Presence of EBV DNA in Cerebrospinal Fluid is Associated with Greater HIV RNA and Inflammation, file e27ce42f-3070-2581-e053-d805fe0acbaa
|
246
|
|
Acute HIV infection: Improved algorithms for HIV testing., file e27ce427-f50f-2581-e053-d805fe0acbaa
|
218
|
|
Disappearance of Renal Stones in an HIV-1-Infected Patient After Reduction of Atazanavir Dose., file e27ce427-0fcf-2581-e053-d805fe0acbaa
|
216
|
|
Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells., file e27ce42a-2054-2581-e053-d805fe0acbaa
|
187
|
|
High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis., file e27ce426-fdb2-2581-e053-d805fe0acbaa
|
183
|
|
Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors., file e27ce42a-3e63-2581-e053-d805fe0acbaa
|
171
|
|
Cardiovascular disease in HIV patients: from bench to bedside and backwards, file e27ce427-460c-2581-e053-d805fe0acbaa
|
163
|
|
Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations., file e27ce426-dd32-2581-e053-d805fe0acbaa
|
160
|
|
Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV, file e27ce430-6596-2581-e053-d805fe0acbaa
|
160
|
|
Transcatheter aortic valve implantation in a 54-year-old patient with aggressive HIV., file e27ce429-0c12-2581-e053-d805fe0acbaa
|
140
|
|
Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity, file e27ce431-c41d-2581-e053-d805fe0acbaa
|
140
|
|
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV, file e27ce42d-d3c3-2581-e053-d805fe0acbaa
|
136
|
|
Extra Corporeal Membrane Oxygenation (ECMO) in three HIV-positive patients with acute respiratory distress syndrome, file e27ce427-0c1c-2581-e053-d805fe0acbaa
|
132
|
|
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014, file e27ce427-f7f3-2581-e053-d805fe0acbaa
|
131
|
|
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study), file e27ce427-493f-2581-e053-d805fe0acbaa
|
129
|
|
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy, file e27ce428-b03e-2581-e053-d805fe0acbaa
|
128
|
|
Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients., file e27ce426-f675-2581-e053-d805fe0acbaa
|
122
|
|
A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients., file e27ce429-063f-2581-e053-d805fe0acbaa
|
119
|
|
Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients, file e27ce429-b6a7-2581-e053-d805fe0acbaa
|
119
|
|
Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort, file e27ce429-a93c-2581-e053-d805fe0acbaa
|
118
|
|
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus, file e27ce429-bd05-2581-e053-d805fe0acbaa
|
116
|
|
Antiretroviral therapy in geriatric HIV patients: The GEPPO cohort study, file e27ce42d-649a-2581-e053-d805fe0acbaa
|
116
|
|
Blood–brain barrier impairment in patients living with hiv: Predictors and associated biomarkers, file e27ce432-7a78-2581-e053-d805fe0acbaa
|
112
|
|
Prevalence and predictors of blood-brain barrier damage in the HAART era., file e27ce428-ccd6-2581-e053-d805fe0acbaa
|
102
|
|
Cytomegalovirus central nervous system compartmentalization in a patient presenting with AIDS, file e27ce429-0fa8-2581-e053-d805fe0acbaa
|
97
|
|
Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage., file e27ce426-d682-2581-e053-d805fe0acbaa
|
95
|
|
Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study, file e27ce42a-5f2a-2581-e053-d805fe0acbaa
|
94
|
|
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort, file e27ce42d-d3bf-2581-e053-d805fe0acbaa
|
91
|
|
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy, file e27ce42e-fdc1-2581-e053-d805fe0acbaa
|
84
|
|
The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment, file e27ce42c-7f76-2581-e053-d805fe0acbaa
|
83
|
|
In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis, file e27ce42d-c454-2581-e053-d805fe0acbaa
|
83
|
|
Co-infection with other respiratory pathogens in COVID-19 patients, file e27ce431-c341-2581-e053-d805fe0acbaa
|
78
|
|
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid, file e27ce42e-f730-2581-e053-d805fe0acbaa
|
71
|
|
Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV, file e27ce431-312c-2581-e053-d805fe0acbaa
|
66
|
|
Heart failure in patients with human immunodeficiency virus: a review of the literature., file e27ce428-cee3-2581-e053-d805fe0acbaa
|
65
|
|
Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection, file e27ce432-0f19-2581-e053-d805fe0acbaa
|
63
|
|
Raltegravir penetration in seminal plasma of healthy volunteers., file e27ce426-cc1e-2581-e053-d805fe0acbaa
|
62
|
|
Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment, file e27ce429-b2bb-2581-e053-d805fe0acbaa
|
62
|
|
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project, file e27ce427-f7f1-2581-e053-d805fe0acbaa
|
57
|
|
What do we know about tailoring treatment with tenofovir?, file e27ce429-0a6b-2581-e053-d805fe0acbaa
|
57
|
|
Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia, file e27ce42d-7235-2581-e053-d805fe0acbaa
|
56
|
|
Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients, file e27ce432-27ed-2581-e053-d805fe0acbaa
|
51
|
|
Class-specific relative genetic contribution for key antiretroviral drugs, file e27ce42a-686a-2581-e053-d805fe0acbaa
|
50
|
|
Detectable cerebrospinal fluid JCV DNA in late-presenting HIV-positive patients: beyond progressive multifocal leukoencephalopathy?, file e27ce42d-33fb-2581-e053-d805fe0acbaa
|
50
|
|
A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs, file e27ce42a-6e2f-2581-e053-d805fe0acbaa
|
46
|
|
Clinical phenotype and contagiousness of early breakthrough SARS-CoV-2 infections after BNT162b2 COVID-19 mRNA vaccine: A parallel cohort study in healthcare workers, file e27ce434-8c4d-2581-e053-d805fe0acbaa
|
46
|
|
Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-positive Patients are Associated with Compartmental Viral Control., file e27ce42a-5667-2581-e053-d805fe0acbaa
|
45
|
|
Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases, file e27ce432-218f-2581-e053-d805fe0acbaa
|
41
|
|
The manifesto of pharmacoenosis: Merging hiv pharmacology into pathocoenosis and syndemics in developing countries, file e27ce433-32b1-2581-e053-d805fe0acbaa
|
41
|
|
Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma, file e27ce431-d047-2581-e053-d805fe0acbaa
|
40
|
|
Analytical validation and clinical application of rapid serological tests for sars-cov-2 suitable for large-scale screening, file e27ce431-e772-2581-e053-d805fe0acbaa
|
38
|
|
Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy, file e27ce432-7646-2581-e053-d805fe0acbaa
|
37
|
|
Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients, file e27ce42f-7b61-2581-e053-d805fe0acbaa
|
36
|
|
Bosentan and Fosamprenavir: an effective and safe combination in an HIV-infected patient with pulmonary arterial hypertension, file e27ce428-a634-2581-e053-d805fe0acbaa
|
34
|
|
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms., file e27ce42a-40fa-2581-e053-d805fe0acbaa
|
33
|
|
Medication Burden and Clustering in People Living with HIV Undergoing Therapeutic Drug Monitoring, file e27ce435-8569-2581-e053-d805fe0acbaa
|
32
|
|
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV, file e27ce435-810a-2581-e053-d805fe0acbaa
|
29
|
|
High incidence of infections in HIV-positive patients treated for lymphoproliferative disorders, file e27ce42d-6343-2581-e053-d805fe0acbaa
|
26
|
|
Etravirine Plasma Exposure is Associated with Virological Efficacy in Treatment-experienced HIV-positive Patients., file e27ce42a-195b-2581-e053-d805fe0acbaa
|
25
|
|
MONITORING OF VIROLOGICAL AND PHARMACOLOGICAL CEREBROSPINAL FLUID PARAMETERS IN HAART-TREATED HIV-POSITIVE PATIENTS IN THE CLINICAL SETTING, file e27ce426-d012-2581-e053-d805fe0acbaa
|
23
|
|
Patterns of Cerebrospinal Fluid Alzheimer’s Dementia Biomarkers in People Living with HIV: Cross-Sectional Study on Associated Factors According to Viral Control, Neurological Confounders and Neurocognition, file e27ce435-6124-2581-e053-d805fe0acbaa
|
22
|
|
Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting, file e27ce42a-e313-2581-e053-d805fe0acbaa
|
18
|
|
Blood Brain Barrier Impairment in HIV-Positive Naïve and Effectively Treated Patients: Immune Activation Versus Astrocytosis, file e27ce42a-e856-2581-e053-d805fe0acbaa
|
18
|
|
On the SARS-CoV-2 "Variolation Hypothesis": No Association Between Viral Load of Index Cases and COVID-19 Severity of Secondary Cases, file e27ce432-0f73-2581-e053-d805fe0acbaa
|
18
|
|
Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment., file e27ce426-eb1c-2581-e053-d805fe0acbaa
|
16
|
|
Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients, file e27ce427-f671-2581-e053-d805fe0acbaa
|
14
|
|
Treating HIV Infection in the Central Nervous System, file e27ce42a-bc75-2581-e053-d805fe0acbaa
|
14
|
|
Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis, file e27ce434-68d1-2581-e053-d805fe0acbaa
|
12
|
|
CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose, file d4de2785-4f79-438d-a6f2-10c847df20d5
|
11
|
|
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid, file e27ce42c-accc-2581-e053-d805fe0acbaa
|
11
|
|
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV, file e27ce433-22d2-2581-e053-d805fe0acbaa
|
11
|
|
Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-Experienced Patients with Skin, Osteoarticular, or Vascular Infections, file cf3e873d-3056-45c4-b40f-a348fd009f60
|
10
|
|
Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment, file e27ce429-b616-2581-e053-d805fe0acbaa
|
9
|
|
Cerebrospinal Fluid Abacavir Concentrations in HIV-positive Patients Following Once-daily Administration, file e27ce42e-f8ce-2581-e053-d805fe0acbaa
|
8
|
|
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial, file e27ce430-ae1f-2581-e053-d805fe0acbaa
|
8
|
|
Enhancing care for people living with HIV: current and future monitoring approaches, file e27ce432-5ef6-2581-e053-d805fe0acbaa
|
8
|
|
Medication Burden and Clustering in People Living with HIV Undergoing Therapeutic Drug Monitoring, file e27ce432-90a4-2581-e053-d805fe0acbaa
|
8
|
|
Determinants of SARS-CoV-2 Contagiousness in Household Contacts of Symptomatic Adult Index Cases, file e27ce435-6126-2581-e053-d805fe0acbaa
|
8
|
|
Real-life Evidence of Lower Lung Virulence in COVID-19 Inpatients Infected with SARS-CoV-2 Omicron Variant Compared to Wild-Type and Delta SARS-CoV-2 Pneumonia, file 1ffebb63-cb7b-46b1-acb4-9f84ca8edd63
|
7
|
|
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid, file e27ce42c-9d4e-2581-e053-d805fe0acbaa
|
7
|
|
Pharmacokinetic Changes during Pregnancy According to Genetic Variants: A Prospective Study in HIV-infected Patients Receiving Atazanavir/Ritonavir, file e27ce42e-7fcb-2581-e053-d805fe0acbaa
|
7
|
|
Antiretroviral Levels in the Cerebrospinal Fluid: The Effect of Inflammation and Genetic Variants, file 571f5786-874f-469d-a28a-706129d78ea1
|
6
|
|
Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-positive Patients are Associated with Compartmental Viral Control., file e27ce428-c2c0-2581-e053-d805fe0acbaa
|
6
|
|
Cytomegalovirus central nervous system compartmentalization in a patient presenting with AIDS, file e27ce429-0fa7-2581-e053-d805fe0acbaa
|
6
|
|
Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study, file 4e1c1b47-d664-43a0-88b1-5ce013526ec1
|
5
|
|
HIV-1 Very Low Level Viremia is Associated with Virological Failure in HAART-treated Patients, file e27ce429-1006-2581-e053-d805fe0acbaa
|
5
|
|
HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing, file e27ce42a-683f-2581-e053-d805fe0acbaa
|
5
|
|
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV, file e27ce42d-d3c2-2581-e053-d805fe0acbaa
|
5
|
|
Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases, file e27ce431-ca65-2581-e053-d805fe0acbaa
|
5
|
|
Concurrent and Subsequent Co-Infections of Clostridioides difficile Colitis in the Era of Gut Microbiota and Expanding Treatment Options, file e1876dec-3e94-4ecd-aba6-c64f2b096920
|
4
|
| Totale |
8903 |